Department of Histopathology, North West London Pathology, Imperial College Healthcare NHS Trusts, London, UK; Department of Metabolism, Digestion and Reproduction, Imperial College Healthcare NHS Trusts, London, UK.
Hematol Oncol Clin North Am. 2024 Dec;38(6):1191-1217. doi: 10.1016/j.hoc.2024.08.017. Epub 2024 Sep 24.
Gestational trophoblastic disease (GTD), comprising hydatidiform moles (HM) and gestational trophoblastic tumors (GTT), is extremely rare. HM originate from villous trophoblast and are considered preneoplastic. GTT originate from the intermediate, largely extravillous trophoblast and includes choriocarcinoma, placental site trophoblastic tumor, epitheloid trophoblastic tumor, and mixed trophoblastic tumor. The abnormal (non-molar) villous lesions, non-malignant tumour-like conditions, and non-gestational tumors add to the diagnostic dilemma. The correct diagnosis and classification of these rare conditions are important. This review intends to provide an update on changes in the World Health Organization classification and focusses on the morphologic aspects in diagnosis of GTD.
妊娠滋养细胞疾病(GTD)包括葡萄胎(HM)和妊娠滋养细胞肿瘤(GTT),极为罕见。HM 来源于绒毛滋养细胞,被认为是癌前病变。GTT 来源于中间型、大部分绒毛外滋养细胞,包括绒毛膜癌、胎盘部位滋养细胞肿瘤、上皮样滋养细胞肿瘤和混合性滋养细胞肿瘤。异常(非葡萄胎样)绒毛病变、非恶性肿瘤样病变和非妊娠性肿瘤增加了诊断的困难。正确诊断和分类这些罕见疾病非常重要。本文旨在介绍世界卫生组织(WHO)分类的变化,并重点讨论 GTD 诊断中的形态学特征。